Search

Your search keyword '"Rauch, Christiane"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Rauch, Christiane" Remove constraint Author: "Rauch, Christiane"
33 results on '"Rauch, Christiane"'

Search Results

2. Serious Games in Academic Education – A Multi-dimensional Sustainability Analysis of Additive Versus Conventional Manufacturing Technologies in a Fictitious Enterprise Project

3. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study

11. Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study

12. AB0361 ASCORE, A 2-YEAR, OBSERVATIONAL, PROSPECTIVE MULTICENTRE STUDY OF SUBCUTANEOUS ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE: 1-YEAR INTERIM ANALYSIS

13. Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study

14. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study

15. Additional file 1: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

16. Additional file 3: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

17. Additional file 2: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

18. Case Reports1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGFβ Receptor Mutations in Benign Joint Hypermobility

19. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

21. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis:24-month results from an international, prospective, real-world study

23. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study

24. Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study

25. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

27. 100. Predictors of Retention with Abatacept in Patients who Have Failed One or More Biologic Agents: Results from the International, Real-World Action Study

28. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

31. Case Reports1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGFβ Receptor Mutations in Benign Joint Hypermobility

32. Phenotype and genotype of 87 patients with Mowat-Wilson syndrome and recommendations for care

33. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.

Catalog

Books, media, physical & digital resources